Efficacy and Safety of Apantamide Combined With Docetaxel and ADT vs. Apantamide Combined With ADT in Patients With High Tumor Burden mHSPC: a Multicenter and Prospective Cohort Study

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Feb 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a combination treatment for men with advanced prostate cancer that has spread to other parts of the body, known as high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC). The trial compares two treatment groups: one receiving apantamide along with docetaxel (a type of chemotherapy) and androgen deprivation therapy (ADT), and the other receiving apantamide with ADT alone. The goal is to see which combination works better for these patients and to monitor any side effects they may experience.

To be eligible for the trial, participants must be adult men aged 18 or older, diagnosed with prostate adenocarcinoma, and have at least four bone metastases or other types of metastases. They should also be beginning treatment with ADT and have good overall health to tolerate the therapies. Throughout the study, participants will receive treatment until they no longer benefit from it, experience unacceptable side effects, or choose to withdraw from the trial. If you or a loved one meets these criteria, participating in this study could provide access to potentially beneficial treatments while contributing to important medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years, male;
• • 2. It was diagnosed as prostate adenocarcinoma by histological or cytological examination, and its pathological type was adenocarcinoma;
• • 3. Bone imaging, CT or MRI showed ≥ 4 bone metastases (≥ 1 bone metastasis located outside the pelvis or spine) or visceral metastasis;
• • 4. .Patients with recurrence after new or local treatment are sensitive to endocrine therapy;
• • 5. Patients receiving ADT treatment (drug or surgical castration), with or without the first generation of antiandrogen drugs, for no more than 3 months, and without evidence of soft tissue imaging disease progression (according to RECIST 1.1 standard) or clinically significant PSA increase (after serum testosterone reaches the castration level, PSA increases by 50% from the lowest level), are allowed to be included in the group;
• • 6. Plan to receive docetaxel combined with apantamide and ADT or apantamide combined with ADT;
• • 7. ECOG PS score 0-1;
• 8. Adequate hematology and organ function:
• • Adequate bone marrow function (no blood transfusion, no use of granulocyte colony stimulating factor): absolute neutrophil count (ANC) ≥ 1.5 × 109/L（1500/ μ L）； Hemoglobin ≥ 90 g/L (9.0 g/dL); Platelet count ≥ 100 × 109/L（100, 000/ μ L）；
• • Adequate liver function: total bilirubin (TBIL) ≤ 1.5 × ULN； AST, ALT and alkaline phosphatase (ALP) ≤ 2.5 times the upper limit of normal value (ULN);
• • Adequate renal function: serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or calculated creatinine clearance ≥ 30 mL/min (calculated using Cockcroft Gault formula);
• • 9. Sufficient coagulation function (without anticoagulation treatment): International normalized ratio (INR) ≤ 1.5;
• Exclusion Criteria:
• • 1. Have a history of hypersensitivity or intolerance to any drug used in the study;
• • 2. Plan to receive any other anti-tumor treatment during the study period;
• • 3. Patients who have received the second generation of androgen receptor (AR) inhibitors in the past, such as apantamide, enzalutamide, darotamide (ODM-201) or other AR inhibitors, CYP17 enzyme inhibitors, such as abietron acetate or oral ketoconazole, chemotherapy or immunotherapy, as well as adjuvant or new adjuvant therapy, should also be excluded;
• • 4. Four weeks before the start of the study, he received plant drugs (such as saw palmetto) that have the effect of anti prostate cancer or reducing PSA level;
• • 5. Have a history of epileptic seizures, a history of medication that can reduce the threshold of epileptic seizures, or a disease that can induce epileptic seizures within 12 months before the start of the study and treatment (including a history of transient ischemic attacks, cerebral apoplexy, brain trauma and disturbance of consciousness requiring hospitalization);
• • 6. There were active heart diseases within 6 months before the start of study treatment, including severe/unstable angina, myocardial infarction, congestive heart failure \[NYHA III or IV\], or arrhythmias requiring drug treatment;
• • 7. There is inability to swallow, chronic diarrhea, intestinal obstruction or other factors affecting drug administration and absorption;
• • 8. Have a history of immunodeficiency (including HIV test positive, other acquired and congenital immunodeficiency diseases) or organ transplantation;
• • 9. Known brain metastasis;
• • 10. Malignant tumors other than prostate cancer in the past 5 years or at the same time, except for cured skin basal cell carcinoma and cervical carcinoma in situ;
• • 11. Those who are receiving any other experimental drugs or experimental medical devices;
• • 12. Poor compliance, difficult to cooperate with treatment and follow-up;
• • 13. The investigator believes that the patient has concomitant diseases (such as poorly controlled hypertension, serious diabetes, neurological or mental diseases, etc.) that seriously endanger the patient's safety, may confuse the research results, or affect the patient to complete the study, or any other situation.